

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/211839 A1

(51) International Patent Classification:

A61K 31/4035 (2006.01) A61P 37/00 (2006.01)
A61K 31/472 (2006.01) C07D 209/46 (2006.01)
A61P 17/04 (2006.01) C07D 217/24 (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2021/027477

(22) International Filing Date:

15 April 2021 (15.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/011,964 17 April 2020 (17.04.2020) US

(71) Applicant: **ESCIENT PHARMACEUTICALS, INC.**

[US/US]; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US).

(72) Inventors: **SAINZ, Marcos**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **YEAGER, Adam**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **SELFRIDGE, Brandon**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **MARTINBOROUGH, Esther**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **BOEHM, Marcus**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **HUANG, Liming**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US).

(74) Agent: **HERMANN, Karl, R.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,


CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS



(57) Abstract: Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R¹, R² and R³ are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided. The Mas-Related G-protein (MRGPR) X4 modulators, are in particular isoindolinones and isoquinolinones substituted on the carbocyclic ring. The compounds are useful to treat itch associated conditions, pain associated conditions, or an autoimmune disorder.

WO 2021/211839 A1